By structurally modifying the K-Ras(G12C) inhibitor, a non-covalent K-Ras(G12D) inhibitor MRTX1133 was developed in late 2021, but twice-daily intraperitoneal administration was required to yield anti-cancer activity in vivo9. The gene discussed is KRAS; the disease is cancer.